Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mepolizumab and exacerbation frequency in refractory eosinophilic asthma
2005-001932-61Phase 2Completed
- Sponsor
- University Hospitals of Leicester NHS Trust
- Start
- Oct 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in eosinophilic asthma (EA) comparing Mepolizumab arm with Placebo arm (2 arms). Primary endpoint: severe exacerbation frequency over 12 months. Started Oct 2005; status: completed.
02
Drugs
mepolizumab
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on 2005-001932-61.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001932-61.